抗PD—L1药物在晚期肿瘤治疗中的应用  

Application of agents of anti-PD-L1 antibody in advanced tumor therapy

作　　者：荆琼优 朴大勋[1] 姜涛[1] 黄宇航[1] 王剑冰[1] 李世强[1] 

机构地区：[1]哈尔滨医科大学附属第一医院结肠直肠外科,150001

出　　处：《国际肿瘤学杂志》2016年第4期296-298,共3页Journal of International Oncology

基　　金：黑龙江省自然科学基金（D201218、ZD201317）

摘　　要：程序性死亡分子1（PD．1）及其配体1（PD-L1）在肿瘤细胞逃避宿主免疫系统的识别和消除中发挥重要作用。小鼠肿瘤模型给予抗PD—L1单抗呈现明显的宿主抗肿瘤反应。目前，PD-1／PD-L1信号通路的免疫治疗药物在多种传统方法治疗失败的肿瘤中收到了良好的效果，且不良反应较小，为晚期肿瘤的免疫治疗提供了宝贵的临床经验。Programmed death-1 （PD-1） and its ligand 1 （PD-L1） play critical roles in the identification and elimination of tumor cells evading the host＇s immune system. Tumor model in mice which is given anti-PD-L1 monoclonal antibody shows obviously host anti-tumor response. Currently, immunotherapy drugs of PD-1/PD-L1 signaling pathways receive good effects in a variety of tumors failure of the traditional method, and with less adverse reaction, which provide valuable clinical experiences in advanced tumor immunotherapy.

关 键 词：肿瘤 免疫疗法 程序性死亡分子配体1 调定点阻滞剂 

分 类 号：R730.5[医药卫生—肿瘤]